Thermo Fisher Scientific Inc TMO
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Thermo Fisher Scientific Inc is a mega-cap company in the Healthcare sector (Diagnostics & Research), with a market value of $242.1B, based in the USA.
It employs about 125,000 people and has been listed since Jan 13, 1978.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 35.2 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 10% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 24.2 — they expect higher earnings.
The average analyst price target is 652.85, 0% below the current price (their view, not ours).
The stock sits at 88% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 14 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (2% fewer shares in a year).
- ✅ Most analysts rate it buy (23 vs 1).
- ✅ Pays a dividend (0.3% a year).
What changed this week
Over the past week the stock fell 3.0% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
It set a new one-year high this week.
This week's news
- Moderna, Illumina lead healthcare gains in September as medtech drags seekingalpha.com · 2026-10-03
- QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel finance.yahoo.com · 2026-10-02
- Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate Automation finance.yahoo.com · 2026-10-01
- Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen finance.yahoo.com · 2026-10-01
- Radiation Detection, Monitoring & Safety Market Forecasts Growth from $3.80B (2026) to $5.68B by 2031, Profiling Fortive, Thermo Fisher & Mirion Technologies finance.yahoo.com · 2026-10-01
- Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption finance.yahoo.com · 2026-09-30
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.